174 related articles for article (PubMed ID: 37403746)
1. Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.
Gui X; Liang X; Li H
Cancer Med; 2023 Aug; 12(16):16793-16804. PubMed ID: 37403746
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract][Full Text] [Related]
4. Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer.
Landry CA; Blanter J; Ru M; Fasano J; Klein P; Shao T; Bhardwaj A; Tiersten A
Oncology; 2024; 102(1):9-16. PubMed ID: 37598677
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
Zhao Y; Xie N; Li W; Chen W; Lv Z; Zheng Y; Sun T; Liu J; Zhang J; Hu S; Wang Y; Gong C; Li Y; Xie Y; Ge R; Xu F; Wang B
Ther Adv Med Oncol; 2021; 13():17588359211030210. PubMed ID: 34290830
[TBL] [Abstract][Full Text] [Related]
6. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
8. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
[TBL] [Abstract][Full Text] [Related]
9. Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting.
Chen CJ; Nguyen HTH; Huang CH; Wang HC; Wu CT; Wu YC; He GY; Chou C; Lin HW; Liu LC
Chemotherapy; 2023; 68(1):23-34. PubMed ID: 36108618
[TBL] [Abstract][Full Text] [Related]
10. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
[TBL] [Abstract][Full Text] [Related]
11. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V; Ricciardi GRR; Giuffrida D; Scandurra G; Russo A; Blasi L; Spadaro P; Iacono C; Soto Parra HJ; Savarino A; Ferraú F; Zerilli F; Verderame F; Butera A; Santangelo C; Franchina V; Caruso M
Ther Adv Med Oncol; 2019; 11():1758835919895755. PubMed ID: 31903098
[TBL] [Abstract][Full Text] [Related]
12. [Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer].
Sang D; Song LH; Di LJ; Wang YL; Liu CG; Guo ZQ; Liu QY; Wang H; Li SY; Yuan P
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):364-369. PubMed ID: 35448926
[No Abstract] [Full Text] [Related]
13. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Hardy-Bessard AC; Brocard F; Clatot F; Lortholary A; You B; Grenier J; Martin-Babau J; Lucas B; Meunier J; Ferrero JM; Savoye AM; Marti A; Despax R; Moullet I; Emile G
Breast; 2020 Dec; 54():256-263. PubMed ID: 33188992
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin (Duomeisu
Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
[TBL] [Abstract][Full Text] [Related]
16. Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life.
Sari M; Saip P
Indian J Cancer; 2020; 57(1):55-61. PubMed ID: 31929236
[TBL] [Abstract][Full Text] [Related]
17. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
18. Eribulin in metastatic breast cancer: Real world data.
Fernández-Laguna CL; Maray I; Macia-Rivas L; Álvarez-Asteinza C; Fernández-Lastras S; Velasco Durántez V; Carbajales Álvarez M; Lozano-Blázquez A
Breast Dis; 2023; 42(1):349-360. PubMed ID: 38073367
[TBL] [Abstract][Full Text] [Related]
19. Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).
Orditura M; Gravina A; Riccardi F; Diana A; Mocerino C; Leopaldi L; Fabozzi A; Giordano G; Nettuno R; Incoronato P; Barzelloni ML; Caputo R; Pisano A; Grimaldi G; Genua G; Montesarchio V; Barbato E; Iodice G; Lieto E; Procaccini E; Mabilia R; Febbraro A; Laurentiis M; Ciardiello F
ESMO Open; 2017; 2(2):e000176. PubMed ID: 28761747
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]